• Pre-existing immune cells can predict early response to hepatitis B vaccine

    Tuesday January 25th 2022

  • ElmediX raises nearly 12 million euros to develop innovative heat technology to fight cancer

    Tuesday January 25th 2022

  • Large UK study shows rapid EGFR testing with Idylla™ alongside NGS has potential to enhance lung cancer patient health outcomes

    Tuesday January 25th 2022

  • Biotalys achieves breakthrough in protein expression increasing commercial potential for its first biofungicide Evoca

    Tuesday January 25th 2022

  • BIMZELX[®] (bimekizumab) approved in Japan for the treatment of plaque psoriasis, generalized pustular psoriasis and psoriatic erythroderma

    Monday January 24th 2022

  • argenx announces VYVGART™ approval in Japan for the treatment of generalized myasthenia gravis

    Friday January 21st 2022

  • Cerba Healthcare enters agreement to acquire Viroclinics-DDL

    Thursday January 20th 2022

  • Ann Van Gysel wordt CEO van flanders.healthTech

    Thursday January 20th 2022

  • Your news here?

  • KU Leuven kiest met Open Data-aanpak resoluut voor Open Wetenschap

    Thursday January 20th 2022

  • Jyseleca®▼ (Filgotinib) licensed for the treatment of adult patients with moderately to severely active ulcerative colitis in Great Britain

    Wednesday January 19th 2022

  • Mithra announces positive top-line results from Donesta® Phase 3 studies in menopausal women

    Friday January 14th 2022

Strategic Partners